People s United Financial Inc. boosted its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 3.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,150 shares of the biotechnology company’s stock after buying an additional 560 shares during the quarter. People s United Financial Inc. owned approximately 0.06% of REGENXBIO worth $339,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the business. Perceptive Advisors LLC lifted its position in REGENXBIO by 8.9% in the 1st quarter. Perceptive Advisors LLC now owns 1,396,244 shares of the biotechnology company’s stock worth $26,947,000 after buying an additional 113,958 shares in the last quarter. Redmile Group LLC purchased a new stake in REGENXBIO in the 1st quarter worth approximately $24,494,000. JPMorgan Chase & Co. lifted its position in REGENXBIO by 4.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,226,835 shares of the biotechnology company’s stock worth $24,230,000 after buying an additional 51,041 shares in the last quarter. Vanguard Group Inc. lifted its position in REGENXBIO by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after buying an additional 100,944 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in REGENXBIO by 65.4% in the 2nd quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after buying an additional 366,289 shares in the last quarter. Institutional investors own 73.26% of the company’s stock.
REGENXBIO Inc. (NASDAQ RGNX) opened at 33.65 on Friday. The stock’s 50 day moving average is $30.08 and its 200 day moving average is $30.08. The firm’s market cap is $1.04 billion. REGENXBIO Inc. has a 52 week low of $15.25 and a 52 week high of $33.95.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.34. The business had revenue of $6.56 million for the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. Equities research analysts expect that REGENXBIO Inc. will post ($2.94) EPS for the current year.
In other news, Director Donald J. Hayden, Jr. sold 20,000 shares of the business’s stock in a transaction on Wednesday, September 27th. The shares were sold at an average price of $32.45, for a total value of $649,000.00. Following the sale, the director now owns 20,000 shares of the company’s stock, valued at $649,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Vittal Vasista sold 3,040 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $21.09, for a total transaction of $64,113.60. Following the completion of the sale, the chief financial officer now directly owns 103,118 shares in the company, valued at approximately $2,174,758.62. The disclosure for this sale can be found here. In the last three months, insiders sold 184,640 shares of company stock worth $4,865,890. 17.00% of the stock is currently owned by insiders.
A number of equities research analysts have issued reports on RGNX shares. Chardan Capital reiterated a “buy” rating and issued a $75.00 target price (up previously from $55.00) on shares of REGENXBIO in a research report on Tuesday, September 5th. Bank of America Corporation increased their target price on shares of REGENXBIO from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, September 21st. Zacks Investment Research downgraded shares of REGENXBIO from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Evercore ISI started coverage on shares of REGENXBIO in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price for the company. Finally, BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. REGENXBIO has an average rating of “Buy” and an average price target of $36.20.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.